ORMP insider buying and SEC filings, explained
Oramed Pharmaceuticals Inc. · CIK 1176309
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$1.2M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 1, 2026 | Planned (10b5-1) | Avraham Gabay (CFO) sold 20,000 shares at about $4.51 ($90K), marked as a 10b5-1 plan trade. Holdings down 2% to 861,076 shares. | SEC filing Filed Oct 2, 2026, 5:19 PM ET |
| Oct 1, 2026 | Planned (10b5-1) | Joshua Hexter (President / COO) sold 30,000 shares at about $4.51 ($135K), marked as a 10b5-1 plan trade. Holdings down 2% to 1,328,130 shares. | SEC filing Filed Oct 2, 2026, 5:19 PM ET |
| Jul 1, 2026 | Planned (10b5-1) | Joshua Hexter (President / COO) sold 137,000 shares at about $4.46 ($611K), marked as a 10b5-1 plan trade. Holdings down 12% to 1,023,384 shares. | SEC filing Filed Jul 2, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Avraham Gabay (CFO) sold 73,360 shares at about $4.51 ($331K), marked as a 10b5-1 plan trade. Holdings down 10% to 671,785 shares. | SEC filing Filed Jul 2, 2026 |
25 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ORMP in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.